<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092417</url>
  </required_header>
  <id_info>
    <org_study_id>V211-009</org_study_id>
    <secondary_id>2004_075</secondary_id>
    <nct_id>NCT00092417</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)</brief_title>
  <official_title>Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka/Merck)Among Adults 50 Years of Age or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the safety and tolerability profile of a higher potency investigational
      vaccine to that of the investigational vaccine at a lower potency dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Vaccine-related Serious Clinical Adverse Experiences (SAEs)</measure>
    <time_frame>Day 1-42 post vaccination</time_frame>
    <description>The incidence of vaccine-related SAEs occurring Day 1 through Day 42 postvaccination. Whether a serious clinical adverse experience occurring Day 1 through Day 42 postvaccination was vaccine-related was determined by the investigator who was a qualified physician . The difference in the risk of developing a vaccine-related SAE between the two groups was compared at the 2-sided 0.05 level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Moderate or Severe Injection-site Pain/Tenderness/Soreness or Swelling (&gt; 2 Inches at Largest Diameter)</measure>
    <time_frame>Day 1-5 postvaccination</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Varicella or Varicella-like Noninjection-site Rashes, Nondermatomal in Distribution With &gt;100 Lesions</measure>
    <time_frame>Day 1-42 postvaccination</time_frame>
    <description>Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be varicelliform rash by the study physician and polymerase chain reaction (PCR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Herpes Zoster (HZ) or HZ-like Rashes</measure>
    <time_frame>Day 1-42 postvaccination</time_frame>
    <description>Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be zosteriform rash by the study physician and polymerase chain reaction (PCR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fevers ≥101.0°F [≥38.3°C]</measure>
    <time_frame>Day 1-21 postvaccination</time_frame>
    <description>Maximum reported oral or equivalent temperature ≥101.0°F [≥38.3°C] was reported Day 1 through Day 21 postvaccination.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">695</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher Potency Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower Potency Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Varicella Zoster Virus Vaccine</intervention_name>
    <description>Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (~207,000 plaque-forming units [PFU]/0.65-mL dose)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Varicella Zoster Virus Vaccine</intervention_name>
    <description>Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (~58,000 plaque-forming units [PFU]/0.65-mL dose)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals 50 years of age or older with a history of chickenpox who have not
             had herpes zoster

        Exclusion Criteria :

          -  Preexisting conditions that might affect vaccine safety such as conditions that
             inhibit an immune response
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW; Protocol 009 Study Group. Safety and tolerability of a high-potency zoster vaccine in adults &gt;/= 50 or years of age. Vaccine. 2007 Feb 26;25(10):1877-83. Epub 2006 Oct 30.</citation>
    <PMID>17227688</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2004</study_first_submitted>
  <study_first_submitted_qc>September 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2004</study_first_posted>
  <results_first_submitted>May 12, 2010</results_first_submitted>
  <results_first_submitted_qc>May 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2010</results_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 18 sites in the United States, Canada, and Europe
Prime Therapy Period: 30-Oct-2003 to 07-Jun-2004
Cutoff date for in-house data: 24-Aug-2004</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoster Vaccine Higher Potency</title>
          <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
        </group>
        <group group_id="P2">
          <title>Zoster Vaccine Lower Potency</title>
          <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="464">Started Period Group 1</participants>
                <participants group_id="P2" count="234">Started Period Group 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="461">3 participants were allocated,not vaccinated; they are not reported in the Baseline Characteristics</participants>
                <participants group_id="P2" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="459">Received the higher potency zoster vaccine &amp; completed 42 days of safety follow-up post vaccination</participants>
                <participants group_id="P2" count="233">Received the lower potency zoster vaccine &amp; completed 42 days of safety follow-up post vaccination</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoster Vaccine Higher Potency</title>
          <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
        </group>
        <group group_id="B2">
          <title>Zoster Vaccine Lower Potency</title>
          <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="461"/>
            <count group_id="B2" value="234"/>
            <count group_id="B3" value="695"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="9.16"/>
                    <measurement group_id="B2" value="65.6" spread="9.69"/>
                    <measurement group_id="B3" value="65.4" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaccine-related Serious Clinical Adverse Experiences (SAEs)</title>
        <description>The incidence of vaccine-related SAEs occurring Day 1 through Day 42 postvaccination. Whether a serious clinical adverse experience occurring Day 1 through Day 42 postvaccination was vaccine-related was determined by the investigator who was a qualified physician . The difference in the risk of developing a vaccine-related SAE between the two groups was compared at the 2-sided 0.05 level.</description>
        <time_frame>Day 1-42 post vaccination</time_frame>
        <population>The population for the primary safety analysis consisted of all vaccinated participants who had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster Vaccine Higher Potency</title>
            <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
          </group>
          <group group_id="O2">
            <title>Zoster Vaccine Lower Potency</title>
            <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine-related Serious Clinical Adverse Experiences (SAEs)</title>
          <description>The incidence of vaccine-related SAEs occurring Day 1 through Day 42 postvaccination. Whether a serious clinical adverse experience occurring Day 1 through Day 42 postvaccination was vaccine-related was determined by the investigator who was a qualified physician . The difference in the risk of developing a vaccine-related SAE between the two groups was compared at the 2-sided 0.05 level.</description>
          <population>The population for the primary safety analysis consisted of all vaccinated participants who had safety follow-up data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With vaccine-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without vaccine-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Moderate or Severe Injection-site Pain/Tenderness/Soreness or Swelling (&gt; 2 Inches at Largest Diameter)</title>
        <time_frame>Day 1-5 postvaccination</time_frame>
        <population>The population for the primary safety analysis consisted of all vaccinated participants who had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster Vaccine Higher Potency</title>
            <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
          </group>
          <group group_id="O2">
            <title>Zoster Vaccine Lower Potency</title>
            <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe Injection-site Pain/Tenderness/Soreness or Swelling (&gt; 2 Inches at Largest Diameter)</title>
          <population>The population for the primary safety analysis consisted of all vaccinated participants who had safety follow-up data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With moderate or severe injection-site reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without moderate or severe injection-site reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Varicella or Varicella-like Noninjection-site Rashes, Nondermatomal in Distribution With &gt;100 Lesions</title>
        <description>Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be varicelliform rash by the study physician and polymerase chain reaction (PCR).</description>
        <time_frame>Day 1-42 postvaccination</time_frame>
        <population>The population for the safety analyses consisted of all vaccinated participants who had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster Vaccine Higher Potency</title>
            <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
          </group>
          <group group_id="O2">
            <title>Zoster Vaccine Lower Potency</title>
            <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Varicella or Varicella-like Noninjection-site Rashes, Nondermatomal in Distribution With &gt;100 Lesions</title>
          <description>Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be varicelliform rash by the study physician and polymerase chain reaction (PCR).</description>
          <population>The population for the safety analyses consisted of all vaccinated participants who had safety follow-up data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With varicella or rash, varicelliform</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without varicella or rash, varicelliform</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Herpes Zoster (HZ) or HZ-like Rashes</title>
        <description>Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be zosteriform rash by the study physician and polymerase chain reaction (PCR).</description>
        <time_frame>Day 1-42 postvaccination</time_frame>
        <population>The population for the safety analyses consisted of all vaccinated participants who had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster Vaccine Higher Potency</title>
            <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
          </group>
          <group group_id="O2">
            <title>Zoster Vaccine Lower Potency</title>
            <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Herpes Zoster (HZ) or HZ-like Rashes</title>
          <description>Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be zosteriform rash by the study physician and polymerase chain reaction (PCR).</description>
          <population>The population for the safety analyses consisted of all vaccinated participants who had safety follow-up data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With zoster or rash, zosteriform</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without zoster or rash, zosteriform</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fevers ≥101.0°F [≥38.3°C]</title>
        <description>Maximum reported oral or equivalent temperature ≥101.0°F [≥38.3°C] was reported Day 1 through Day 21 postvaccination.</description>
        <time_frame>Day 1-21 postvaccination</time_frame>
        <population>The population for the safety analyses consisted of all vaccinated participants who had safety follow-up data. 5 participants in the Zoster Vaccine Higher Potency group and 3 participants in the Zoster Vaccine Lower Potency group were not included in this analysis since these participants were without a follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster Vaccine Higher Potency</title>
            <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
          </group>
          <group group_id="O2">
            <title>Zoster Vaccine Lower Potency</title>
            <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fevers ≥101.0°F [≥38.3°C]</title>
          <description>Maximum reported oral or equivalent temperature ≥101.0°F [≥38.3°C] was reported Day 1 through Day 21 postvaccination.</description>
          <population>The population for the safety analyses consisted of all vaccinated participants who had safety follow-up data. 5 participants in the Zoster Vaccine Higher Potency group and 3 participants in the Zoster Vaccine Lower Potency group were not included in this analysis since these participants were without a follow-up.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With max oral temp ≥101.0°F (≥38.3°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With max oral temp &lt;101.0°F (&lt;38.3°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 – 42 postvaccination</time_frame>
      <desc>Daily temperature readings, injection-site adverse experiences, rashes, and other adverse experiences were recorded by the participant on a Vaccination Report Card which was reviewed 42 days after vaccination.
Number of participants at risk included randomized participants who had follow-up after at least one dose of vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zoster Vaccine Higher Potency</title>
          <description>Higher potency Zoster vaccine (approximately 207,000 plaque-forming units [PFU]), 1 subcutaneous 0.65 mL injection</description>
        </group>
        <group group_id="E2">
          <title>Zoster Vaccine Lower Potency</title>
          <description>Lower potency Zoster vaccine (approximately 58,000 PFU), 1 subcutaneous 0.65 mL injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 7.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="296" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

